The Business Times
business-time-50
SUBSCRIBERS

Lonza in joint venture to develop biotherapeutic products

google-preferred-sourceAdd BT as a preferred source

Ng Ren Jye

Published Wed, Apr 3, 2019 · 09:50 PM

Singapore

SWISS biotech company Lonza has entered into an equal joint venture (JV) with Danish bioscience company Chr Hansen Holding to develop live biotherapeutic products (LBP) for pharma and biotech customers.

The phased investment of about 90 million euros (S$136.6 million) will be shared equally between the partners over three years.

lonza

TRENDING NOW

Longest-serving chief minister Taib Mahmud’s legacy looms large over Sarawak as a family feud over his estate threatens to expose skeleton’s in the eastern state’s political closet.

On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart

State-level minimum purchase thresholds push foreign buyers towards higher-value properties, while consent rules and other restrictions further narrow the pool of homes available to them.

That ‘cheap’ Malaysia condo could cost Singapore buyers far more than they think

The Business Times looks at what is fuelling the surge in these tiny tech counters, and whether the momentum can last.

These little-known SGX tech stocks are beating the market. What’s driving them up? 

The benchmark Jakarta Composite Index dropped as much as 1.7% intraday to its lowest level since late April 2025.

Indonesia equities plunge as MSCI removal triggers broad sell-off; tycoon-linked stocks hit hardest

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More